Exhibits at the Military Health System Research Symposium displayed the future of medical technology and the concepts and innovations that are under development, including several products currently scheduled for testing.
CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translati.